Make Every Day Independence Day.
Joint discomfort can rob a person of their ability to do the simple things in everyday life. Every moment’s loss of mobility seems like an eternity.
With 5-LOXIN, you can help your customers get their freedom to move back faster. Clinical studies have shown that a small 100 mg dose of 5-LOXIN reduces joint discomfort and enhances flexibility in as little as 7 days.
Around the world, people have turned to 5-LOXIN as a drug-free approach to joint comfort. They trust the science. Trust the quality. And trust the experience.
Boswellic acids are natural, selective 5-lipoxygenase inhibitors. 3-O-acetyl-11-keto-ß-boswellic acid or “AKBA” is the most active.
5-LOXIN® provides a higher concentration of AKBA, standardized to 30%.
In a human study, both 100mg and 250mg of 5-LOXIN® daily provided improvement in joint comfort and mobility within 7 days.
5-LOXIN® provided significant benefits in WOMAC, VAS and LFI standardized testing methodologies for joint health.
5-LOXIN® positively impacted biological markers associated with joint and general health, including TNFa, CRP, and IL-6.
5-LOXIN® was shown to significantly inhibit matrix metalloproteinase (MMP-3), enzymes that break down cartilage, collagen and connective tissues.
5-LOXIN® is well-tolerated, easy on the stomach and supported by extensive safety data.
Fifteen Studies and Counting
5-LOXIN is a novel Boswellia serrata extract enriched with 30% 3-O-acetyl-11-keto-beta-boswellic acid (AKBA), which exhibits potential anti-inflammatory properties by inhibiting the 5-lipoxygenase enzyme. In joint health products, it is used both as a standalone ingredient and in conjunction with other ingredients to power some of the best-known joint health consumer brands in the world.
5-LOXIN has been the subject of 13 pre-clinical studies and 2 human clinical trials. One of the key features of 5-LOXIN in any formulation is clinical work that has demonstrated efficacy starting at 7 days – at a significantly lower dose (100 mg) than other joint health ingredients. This fast efficacy and low dose allow 5-LOXIN to compete with non-natural or over-the-counter solutions.
Beyond joint comfort and flexibility improvements, 5-LOXIN also positively impacts biological markers associated with joint health and inflammation, including TNFa, CRP, and IL-6. It was also shown to significantly inhibit matrix metalloproteinase (MMP-3), enzymes that break down cartilage, collagen and connective tissues.
5-LOXIN is derived from Boswellia serrata gum resin and contains 30% AKBA. It was the first entrant into PLT’s global portfolio of AKBA-based joint health ingredients.
The starting point for 5-LOXIN – Boswellia serrata – is a plant that produces Indian frankincense. It is also known as Indian olibanum, Salai guggul, and Sallaki in Sanskrit. The plant is native to much of India and the Punjab region that extends into Pakistan. In partnership with Laila, PLT is committed to the safety and fair treatment of the people who harvest 5-LOXIN. We want to support the long-term health and well-being of the tribal culture and the natural environment upon which it relies.
Every batch of the 5-LOXIN harvest is assigned a specific batch number and each batch of finished product is traceable to a specific region and set of trees. 5-LOXIN is tested and must comply with predefined specifications for different parameters at different stages of product manufacturing – from raw materials to finished product. Quality is monitored by a multi-disciplinary organization with dedicated departments for taxonomy (botanical Identification), raw material analysis, chemical analysis, microbiology, and more.